logo
How this TB triage tool experiment in Tamil Nadu reduced death by 20 per cent: Can it be used in national programmes?

How this TB triage tool experiment in Tamil Nadu reduced death by 20 per cent: Can it be used in national programmes?

Indian Express08-07-2025
A simple five-question triage tool — without the need for any laboratory tests — may be the key to saving lives of people diagnosed with tuberculosis (TB). Within two quarters of implementation in Tamil Nadu, the tool resulted in a state-wide reduction of early TB deaths — deaths recorded within the first two months of initiating TB treatment — by 20 per cent.
In fact, two-thirds of the total districts in the state documented a 20 per cent to 30 per cent reduction in total deaths in 2024. Discussions are ongoing to implement a similar tool under the national programme. There were an estimated 28 lakh TB cases and 3.15 lakh deaths in India in 2023, according to the latest available data from the Global TB Report.
Health workers in the state record five key parameters for all TB patients in the state — height and weight for calculating the body mass index (BMI) which can flag undernutrition in TB patients, swelling of the leg by pressing it for 15 seconds, respiratory rate per minute in a sitting position, oxygen saturation on a pulse oximeter and ability to stand without support.
A patient is tagged severely ill if they have any one condition — severe undernutrition indicated by BMI of less than 14kg/m2, respiratory insufficiency as indicated by the respiratory rate and oxygen saturation, or poor performance status as indicated by their inability to stand. The 'severely ill' patients are immediately referred for comprehensive assessment and inpatient treatment.
'Immediate in-patient care can reduce the probability of early death in the severely ill patients between one per cent and four per cent. Otherwise, the probability of death in these patients is between 10 per cent and 50 per cent,' said Dr Hemant Shewade, senior scientist from the National Institute of Epidemiology, who has studied the implementation of the initiative called Tamil Nadu-Kasanoi Erappila Thittam (TN-KET).
The initiative, rolled out in 2022, is the first state-wide implementation of the country's differentiated treatment guidelines, which aims to provide more support to severely ill patients. The implementation over the last couple of years demonstrates the feasibility and effectiveness of differentiated care models. And, it goes a step beyond, to show that the triaging process can be shorter and quicker.
The tool used in Tamil Nadu depends on just five parameters, instead of the nationally recommended 16 parameters. The triaging is performed by the health workers in the state within a day of diagnosis, with 98 per cent of those confirmed to have severe illness admitted to a hospital within seven days of diagnosis.
While the tool can be used with just pen and paper, the TN government has a portal called Severe TB Web Application. 'Now, this portal will have a prediction of the probability of a patient dying when the parameters are entered. This will help guide the health workers to take immediate action and prevent TB deaths,' said Dr Manoj Murhekar, head of the National Institute of Epidemiology.
The research from the institute has not only led to successful reduction of deaths due to TB but also in several interventions that have now been included in the national programme. One such intervention was increasing the monetary nutritional support provided by the government from Rs 500 to Rs 1,000. Importantly, the first three instalments of this monetary support are provided at the time of diagnosis.
Dr Shewade said, 'Our research found that in many cases there were delays in providing the monetary support, with many experiencing adverse outcomes before they got the support. We know that half of all the TB deaths that have to happen, happen within the first two months. And, without proper nutrition, the treatments are not likely to be as effective. This was the evidence behind the change in policy.'
An evaluation of the national programme by the NIE showed that patients, on average, received the first instalment of their monetary nutritional support 91 days after the diagnosis. In fact, two thirds of the patients with an unfavourable outcome received the support after their outcome was declared, according to the evaluation. The evaluation also suggested doubling the monthly rations for those with severe and very severe under-nutrition — a suggestion that has not yet been implemented as part of the national programme.
Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme.
Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports.
Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan.
She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times.
When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cy-TB test introduced by Kerala govt. for detecting and treating tuberculosis
Cy-TB test introduced by Kerala govt. for detecting and treating tuberculosis

The Hindu

time3 hours ago

  • The Hindu

Cy-TB test introduced by Kerala govt. for detecting and treating tuberculosis

The State health authorities in Kerala have introduced a new intradermal test called Cy-TB for detecting and treating tuberculosis (TB) infection following the prioritisation of latent TB infection treatment under the National TB Elimination Programme (NTEP). TB infection is different from active TB disease. A person with TB infection harbours the organism causing TB infection (Mycobacterium tuberculosis) in the body, having probably acquired it through contact with someone with active disease. But the organism remains dormant or inactive in the body and the person neither has any TB symptoms nor is he contagious. However, if left untreated, 5-10% of them will progress to developing active TB disease when the body's immune system weakens, allowing the TB bacteria to flare up. This could happen within weeks of acquiring the infection or maybe years, depending on the immune system and other factors determining immune regulation. Study A community-based cross-sectional study among adults in Thiruvananthapuram district in 2023 had reported that roughly one-fifth of the adult population in the district – 20.5% of adults – have tuberculosis infection. The study, 'Prevalence of Tuberculosis Infection among Adults of Thiruvananthapuram District of Kerala as Measured by Interferon Gamma Release Assay – A Cross-Sectional Study,' tested whole blood samples of 396 adults in Thiruvananthapuram for TB infection and found that the prevalence of TB infection increased with age, ranging from 11.5% in the 18-35 age group to 30.3% in the 58-years-plus age group. 'Our studies show that about 22% of the State's general population has acquired TB infection from the community. While they pose no immediate threat to the community, once they go into an immuno-compromised state, the bacteria will multiply and produce symptoms of active disease. Given the morbidity profile of Kerala – high prevalence of diabetes, chronic kidney disease, heavy alcohol use and a huge population on dialysis – it is important that we identify and treat these people to reduce the future burden of TB,' says Aparna Mohan, Government of India-WHO consultant for TB. Cy-TB is a third generation test approved by the Central TB Division. Blood test detection Since 2021, Kerala has been using the blood test Interferon Gamma Release Assay (IGRA) for detecting TB infection. However, this test required extensive laboratory support and it had a waiting period too. There were also systemic difficulties in rolling it out. Cy-TB is a highly specific, accurate and user-friendly skin test, wherein 0.1 ml dose of M. tuberculosis-specific antigens (ESAT-6 and CFP-10) are injected into the skin in the inner forearm. An induration (a raised area) of 5 mm or more which develops on the skin within 48-72 hours indicates TB infection (While a trained nurse can administer the injection, the person will have to return to the health centre for checking out the skin reaction.) If tested positive, active TB has to be ruled out before considering TB preventive therapy. TB preventive therapy is optional and not currently recommended for all those who are infected. Only high risk individuals recommended for preventive therapy under the NTEP alone need to take preventive therapy. Risk groups In Kerala, the identified risk groups include individuals on immunosuppressive therapy, those with silicosis (lung disease following the inhalation of silica dust), those on anti-TNF treatment, and those on dialysis and awaiting organ transplantation. Preventive therapy is also offered to health-care workers who test positive in the Cy-TB test. The preventive therapy is a short regimen with less number of drugs. This could be three-month weekly Isoniazid and Rifapentine (3HP) or six-months daily Isoniazid (6H). According to the State TB Division, Cy-TB will be offered in district TB centres, taluk hospitals, at the block level in some districts and in all dialysis centres too. The Health department also intends to use Cy-TB to test inmates in old age homes where pulmonary TB has been reported. The test is currently available in major private hospitals too.

Higher Dose of This Antibiotic Can Help In Tuberculosis Recovery: Study
Higher Dose of This Antibiotic Can Help In Tuberculosis Recovery: Study

NDTV

time2 days ago

  • NDTV

Higher Dose of This Antibiotic Can Help In Tuberculosis Recovery: Study

New Delhi: A higher dose of rifampicin -- a bactericidal antibiotic used primarily to treat tuberculosis (TB) -- may be safe, and its use can potentially lead to recurrence-free survival in patients with pulmonary TB, according to a recent study by the Indian Council of Medical Research (ICMR). TB is curable but still remains the most common cause of death due to infectious diseases, with an estimated 1.3 million deaths globally in 2022. Rifamycins are a crucial drug group in the anti-TB regimen, which sterilise the lesions and aid in recurrence-free cure. Currently, rifampicin is administered at 10 mg/kg for six months to all patients with pulmonary TB. The team reviewed the available evidence from published clinical trials to determine whether higher doses of rifampicin (more than 15 mg/kg) are more efficacious and safer. "Compared to standard dose, higher doses of rifampicin were found to lead to early sputum conversion in eight weeks and thus faster TB bacteria clearance," said corresponding author Dr Leeberk Raja Inbaraj, Department of Clinical Research, ICMR- National Institute for Research in Tuberculosis, Chennai. Early sputum conversion is a valuable tool widely used as a surrogate marker for treatment response and those who are at risk for relapse in pulmonary TB. "The ability of high-dose rifampicin to achieve early sputum conversion and eliminate the persistent bacteria that cause relapse could potentially lead to recurrence-free survival. Early bacterial clearance is also of public health importance as this could potentially reduce disease transmission in the community," the researchers said. Notably, the study showed 20-30mg/kg rifampicin as the best balance. "This dose range showed better sputum conversion without a significant increase in serious side effects and may be considered in TB treatment," revealed the study, published in the Indian Journal of Medical Research (IJMR). On the other hand, doses above 30 mg/kg, although beneficial, came with severe side effects such as serious liver damage (hepatotoxicity) and adverse drug reactions (ADR), leading to treatment discontinuation. The study showed no reduction in death or treatment failure in people with more than 15 mg/kg doses of rifampicin. "High doses did not reduce mortality or treatment failure at 6 months compared to standard treatment," the team said. "This dose could be administered with close monitoring of adverse events and hepatotoxicity. There is an urgent need for adequately powered trials that assess long-term treatment outcomes, including recurrence," they added.

Lung TB: Higher dose of rifampicin safe, can boost recurrence-free survival, says ICMR study
Lung TB: Higher dose of rifampicin safe, can boost recurrence-free survival, says ICMR study

Hans India

time2 days ago

  • Hans India

Lung TB: Higher dose of rifampicin safe, can boost recurrence-free survival, says ICMR study

New Delhi: A higher dose of rifampicin -- a bactericidal antibiotic used primarily to treat tuberculosis (TB) -- may be safe, and its use can potentially lead to recurrence-free survival in patients with pulmonary TB, according to a recent study by the Indian Council of Medical Research (ICMR). TB is curable but still remains the most common cause of death due to infectious diseases, with an estimated 1.3 million deaths globally in 2022. Rifamycins are a crucial drug group in the anti-TB regimen, which sterilise the lesions and aid in recurrence-free cure. Currently, rifampicin is administered at 10 mg/kg for six months to all patients with pulmonary TB. The team reviewed the available evidence from published clinical trials to determine whether higher doses of rifampicin (more than 15 mg/kg) are more efficacious and safer. 'Compared to standard dose, higher doses of rifampicin were found to lead to early sputum conversion in eight weeks and thus faster TB bacteria clearance,' said corresponding author Dr Leeberk Raja Inbaraj, Department of Clinical Research, ICMR- National Institute for Research in Tuberculosis, Chennai. Early sputum conversion is a valuable tool widely used as a surrogate marker for treatment response and those who are at risk for relapse in pulmonary TB. 'The ability of high-dose rifampicin to achieve early sputum conversion and eliminate the persistent bacteria that cause relapse could potentially lead to recurrence-free survival. Early bacterial clearance is also of public health importance as this could potentially reduce disease transmission in the community,' the researchers said. Notably, the study showed 20-30mg/kg rifampicin as the best balance. 'This dose range showed better sputum conversion without a significant increase in serious side effects and may be considered in TB treatment,' revealed the study, published in the Indian Journal of Medical Research (IJMR). On the other hand, doses above 30 mg/kg, although beneficial, came with severe side effects such as serious liver damage (hepatotoxicity) and adverse drug reactions (ADR), leading to treatment discontinuation. The study showed no reduction in death or treatment failure in people with more than 15 mg/kg doses of rifampicin. 'High doses did not reduce mortality or treatment failure at 6 months compared to standard treatment,' the team said. 'This dose could be administered with close monitoring of adverse events and hepatotoxicity. There is an urgent need for adequately powered trials that assess long-term treatment outcomes, including recurrence,' they added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store